Does adherence to a prescribed exercise program change how much cognition improves, and can adherent people benefit at lower doses?

Why researchers keep asking about adherence

A prescribed program only works to the extent people do it, so adherence — the share of the planned sessions or dose someone actually completes — is an obvious suspect when cognitive results come out uneven. In a pilot randomized trial of a home-based cognitive training program (BrainHQ) for gynecologic cancer survivors, adherence to the full prescribed dose was variable across participants [2]. The trial's qualitative findings pointed toward refining the intervention dose and how adherence is supported, and participants described the training as an active strategy to improve cognition [2]. That framing is important: the study documents that people did not all complete the prescribed amount, and that this variability is worth designing around, rather than demonstrating that the more adherent participants improved more.

Can a smaller dose still sharpen thinking?

For exercise specifically, the strongest signal comes from a network meta-analysis of 44 randomized trials covering 4,793 older adults, which modeled cognition against exercise dose rather than comparing adherence levels [3]. The relationship was non-linear, and the authors found no minimal threshold below which exercise stopped helping cognition [3]. The estimated dose associated with clinically relevant cognitive change was 724 METs-min per week — METs-min being a way of combining how hard an activity is with how long it lasts — and doses above roughly 1,200 METs-min per week gave less clear additional benefit [3]. In plain terms, the curve rises and then flattens; piling on more exercise past a point does not reliably buy more cognition.

The same analysis found that the dose-response curve depended on the type of exercise, and that clinically important effects may occur at lower doses for many exercise types, with resistance training standing out as the most potent modality [3]. The authors concluded that older adults can get clinically meaningful benefits at doses below WHO guideline levels when the exercise type is well chosen [3]. This is a statement about dose, not about adherence: it tells us a smaller prescription can be enough, not that people who follow a prescription more faithfully do better.

Does adherence change the size of the benefit?

The two threads do not yet connect cleanly. The dose analysis shows a ceiling effect — benefits appear at modest doses and become less clear at high ones [3] — which would tend to weaken any simple story in which more adherence always means more cognitive gain. If a low dose already captures most of the benefit, then completing 100% of a high-dose prescription may not outperform completing 60% of it.

The cancer-setting studies add a practical caution. In the multicomponent resistance-based program with protein, vitamin D and calcium supplementation for men with prostate cancer, exercise adherence was monitored alongside cognitive outcomes, and the abstract notes that exercise below recommended guidelines did not support a cognitive benefit in that context [1]. That sits in tension with the older-adult dose findings [3], and the difference in populations — men undergoing prostate cancer treatment versus generally healthy older adults — is a plausible reason the answers diverge. It is also a reminder that "lower doses work" is a population-specific claim, not a universal one.

In the cognitive-training pilot, the takeaway was procedural rather than dose-related: variable adherence to the full prescribed dose motivated the authors to refine the dose and adherence support in future work [2]. Neither cancer study isolates adherence as the variable that predicts cognitive change, so the honest answer is that adherence is a reasonable hypothesis and a design concern, not a demonstrated lever.

What this means if you are choosing a program

If the goal is cognition, the evidence favors picking a modality with a strong track record — resistance exercise is the clearest example in the older-adult data [3] — and hitting a moderate dose rather than maximizing volume. The absence of a minimum threshold and the flattening above about 1,200 METs-min per week suggest that a sustainable, moderate routine is a sensible target [3].

Adherence still deserves attention, but for a different reason than "more is better." The pilot trial's experience suggests that a prescription people cannot realistically complete should be revised, and that support for sticking with a program is part of the intervention rather than an afterthought [2]. For men in prostate cancer treatment, the picture is less encouraging at sub-guideline exercise levels [1], so a clinician-guided program at recommended levels remains the safer default there until more evidence arrives.

Sources used in this answer

Related research questions